Tophaceous Gout and Renal Insufficiency: A New Solution for an Old Therapeutic Dilemma
Author(s) -
AnneKathrin Tausche,
Carsten Wunderlich,
Martin Aringer
Publication year - 2011
Publication title -
case reports in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.2
H-Index - 20
eISSN - 1687-9627
pISSN - 1687-9635
DOI - 10.1155/2011/397646
Subject(s) - medicine , gout , febuxostat , benzbromarone , allopurinol , gouty arthritis , probenecid , uric acid , xanthine oxidase inhibitor , renal function , sulfinpyrazone , polyarthritis , gastroenterology , arthritis , hyperuricemia , xanthine oxidase , surgery , aspirin , biochemistry , chemistry , enzyme
The prevalence of gout is increasing with increased life expectancy. Approximately half of the patients with gout have some degree of renal impairment. If both conditions persistently coexist, and in severe tophaceous gout, in particular, treatment has been difficult. We here report on the case of an 87-year-old woman, who had been suffering from recurrent gouty arthritis over 4 years. Monthly polyarthritis attacks were accompanied by subcutaneous tophi. Serum uric acid levels were constantly above 600 μ mol/L (10 mg/dL). Allopurinol was no option because of intolerance, while benzbromarone was ineffective because of renal impairment. Therefore, the novel xanthin oxidase inhibitor febuxostat was started, achieving rapid control of serum urate levels (<360 μ mol/L). After initial worsening of inflammation in the first weeks, gouty attacks stopped and all tophi resolved within the following 10 months. Renal function remained stable.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom